
RF Acquisition Corp II
46
Recent developments include shareholder approval of the merger with Nanyang Biologics and the announcement of the business combination agreement, which have significantly impacted the company's share price and business outlook.
- On August 21, 2026, RF Acquisition Corp II shareholders approved the merger vote with Nanyang Biologics, resulting in a 230% increase in the company's shares [N1].
- On October 2, 2025, the company entered into a business combination agreement with Nanyang Biologics Pte. Ltd. in a $1.5 billion transaction to pursue a public listing [N2].
- The9's Singapore investee Nanyang Biologics announced plans to go public via the business combination with RF Acquisition Corp II on October 2, 2025 [N3].
- In September 2024, the company announced an updated per share redemption price in connection with an upcoming special meeting [N4].
RF Acquisition Corp II operates as a special purpose acquisition company (SPAC) with the objective of effecting a business combination with one or more companies primarily in Asia's deep technology sector. The company focuses on targets in artificial intelligence, quantum computing, and biotechnology. It completed its IPO in May 2024, raising gross proceeds of approximately $115.6 million, which were placed in a trust account invested in U.S. government securities. The company has a limited operating history and generates income primarily from interest on IPO proceeds until a business combination is consummated. The company has a deadline of August 15, 2026, to complete a business combination. It has entered into a definitive agreement to merge with Nanyang Biologics, an AI drug discovery company, in a transaction valued at $1.5 billion. Shareholders approved this merger in August 2026, which led to a significant increase in the company's share price.
RF Acquisition Corp II is a Cayman Islands exempted blank check company formed in 2024 to pursue a business combination primarily targeting Asian deep technology companies in AI, quantum computing, and biotechnology. The company completed its IPO in May 2024, raising over $115 million placed in a trust account. As of September 30, 2026, the company reported minimal liquidity and a net loss for the quarter. It entered into a $1.5 billion business combination agreement with Nanyang Biologics, an AI drug discovery firm, with shareholder approval received in August 2026. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The company has secured a business combination agreement with Nanyang Biologics, an AI drug discovery pioneer, in a $1.5 billion transaction that aims to bring the target public via Nasdaq listing. The shareholder approval of the merger vote and the subsequent share price increase demonstrate market validation of the transaction. The management team's focus on deep technology sectors with high growth potential and their operational and capital markets experience could support value creation post-merger.
The company currently has minimal liquidity outside of the trust account and reported a net loss for the recent quarter, reflecting its status as a blank check company without operating revenues. The success of the business model depends entirely on consummating the business combination and the subsequent performance of the combined entity. Risks include failure to complete the merger within the deadline, potential dilution, and uncertainties related to the target company's operations and market acceptance.
As a SPAC, RF Acquisition Corp II's moat is primarily derived from its management team's expertise and network in sourcing and executing business combinations in the deep technology sector in Asia. The company's ability to identify and consummate a business combination with a market-leading target in AI, quantum computing, or biotechnology could create value through operational expertise and access to public capital markets. However, as a blank check company without operating revenues or assets beyond the trust account, its moat is contingent on successful execution of its business combination strategy.
• Business Combination Completion Risk: Failure to complete a business combination within the prescribed timeframe could result in liquidation and loss of shareholder value (S1).
• Liquidity Risk: The company reported very low liquidity ratios and zero cash and equivalents as of September 30, 2026, which may constrain operational flexibility (S2).
• Market and Execution Risk: The success of the business model depends on the performance of the target company post-merger and the ability to realize synergies and growth in the deep technology sector.
Business trends: The company is transitioning from a blank check entity to a public operating company through a business combination with an AI drug discovery firm.
Execution milestones: Completion of the business combination with Nanyang Biologics and integration of the combined entity.
Key risks: Completion risk of the business combination, liquidity constraints, and operational risks related to the target company's performance.
Moderate visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
Generated 2026-11-12
- S1 | 2026-02-11 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-08-21 | www.nasdaq.com | RF Acquisition Corp II Shares Explode 230% On Nanyang Biologics Merger Vote Approval | https://www.nasdaq.com/articles/rf-acquisition-corp-ii-shares-explode-230-nanyang-biologics-merger-vote-approval
- N2 | 2025-10-02 | www.nasdaq.com | AI Drug Discovery Pioneer, Nanyang Biologics Pte. Ltd., Enters into Business Combination Agreement with RF Acquisition Corp II in US$1.5B Transaction to Pursue Public Listing | https://www.nasdaq.com/press-release/ai-drug-discovery-pioneer-nanyang-biologics-pte-ltd-enters-business-combination
- N3 | 2025-10-02 | www.nasdaq.com | The9's Singapore Investee NYB Announce Plan to Go Nasdaq via US$1.5 Billion Business Combination with SPAC RF Acquisition Corp II | https://www.nasdaq.com/press-release/the9s-singapore-investee-nyb-announce-plan-go-nasdaq-us-15-billion-business
- N4 | 2024-09-17 | www.nasdaq.com | RF Acquisition Corp. Announces Updated Per Share Redemption Price in Connection With Upcoming Special Meeting | https://www.nasdaq.com/press-release/rf-acquisition-corp-announces-updated-share-redemption-price-connection-upcoming
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


